Dry Powder Inhaler Devices Market: By Type; By Therapeutics & By Region - Forecast 2016-2022

  • ID: 4033504
  • Report
  • 176 pages
  • IndustryARC
1 of 3
Dry-powder inhaler (DPI) is an alternative device to the aerosol-based inhalers commonly called metered-dose inhaler (or MDI) and help in delivering medication to the lungs in the form of a dry powder. DPIs are commonly used to treat respiratory diseases such as asthma, bronchitis, emphysema and COPD, although DPIs (such as inhalable insulin Afrezza) have also been used in the treatment of diabetes mellitus. Globally, increasing number of people with respiratory diseases and diabetes mellitus are expected to remain the growth drivers for dry powder inhaler devices during the period of study.

Dry Powder Inhaler Devices Market

Geographically, North America dominated the dry powder inhaler devices market driven by a world class healthcare infrastructure with a technologically advanced practice, higher spending, a high number of people with respiratory problems, strict guidelines and presence of key industry players in the region. North America was followed by Europe and Asia-Pacific as second and third largest market for dry powder inhaler devices market. Asia Pacific is projected to have the fastest growth, owing to a rapidly developing medical infrastructure, increasing spending on healthcare and growing medical tourism in developing nations such as China and India in this region.

This report identifies the dry powder inhaler devices market size for the years 2014-2016, and forecast of the same till the year 2022. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the dry powder inhaler devices market.

This report segments the dry powder inhaler devices market on the basis of type, therapeutics and regional market as follows:

Dry powder inhaler devices market research report is classified on the basis of type. Some of the major types covered in this report are as follows: Capsule Based Dry Powder Inhaler Device, Blister Based Powder Inhaler Device, Reservoir/Cartridge Based Powder Inhaler Device and Others
Dry powder inhaler devices market research report is classified on the basis of therapeutics. Some of the major therapeutics covered in this report are as follows: Upper Respiratory, Asthma, COPD, Diabetes, Hereditary Diseases, Cystic Fibrosis, Infectious Diseases, Osteoporosis, Neurology, Pain Management
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the dry powder inhaler devices market. Some of the major companies’ profiles in detail are as follows:

Bayer HealthCare AG Company
GlaxoSmithKline Plc
Sandoz International GmbH
Teva Pharmaceutical Industries Ltd.

Novartis AG
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Dry powder inhaler devices Market – Overview

2. Executive Summary

3. Dry powder inhaler devices Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis

4. Dry powder inhaler devices Market– Forces
4.1. Drivers
4.1.1. Increasing population with respiratory problems
4.1.2. Technological advancement
4.2. Restraints
4.3. Opportunities
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Dry powder inhaler devices Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Dry powder inhaler devices Market, By Type
6.1. Capsule Based
6.2. Blister Based
6.3. Reservoir/Cartridge Based
6.4. Others

7. Dry powder inhaler devices Market, By Therapeutics
7.1. Upper Respiratory
7.2. Asthma
7.3. COPD
7.4. Diabetes
7.5. Hereditary Diseases
7.6. Cystic Fibrosis
7.7. Infectious Diseases
7.8. Osteoporosis
7.9. Neurology
7.10. Pain Management
7.11. Others

8. Dry powder inhaler devices Market, By Geography
8.1. Europe
8.1.1. Germany
8.1.2. France
8.1.3. Italy
8.1.4. Spain
8.1.5. Russia
8.1.6. U.K.
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.1. China
8.2.2. India
8.2.3. Japan
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.3.1. U.S.
8.3.2. Canada
8.3.3. Mexico
8.4. Rest of the World (RoW)
8.4.1. Brazil
8.4.2. Rest of RoW

9. Dry powder inhaler devices Market – Entropy
9.1. Expansion
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract

10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
10.1. Bayer HealthCare AG Company
10.2. GlaxoSmithKline Plc
10.3. Sandoz International GmbH
10.4. Teva Pharmaceutical Industries Ltd.
10.5. Novartis AG
10.6. AKELA Pharma Inc.
10.7. Pharmaxis Limited
10.8. Hovione FarmaCiencia SA
10.9. Nanotherapeutics, Inc
10.10. OPKO Health, Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Research Methodology
11.4. Bibliography
11.5. Compilation of Expert Insights
11.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll